![](/images/graphics-bg.png)
Adipose-Derived Stromal Cells for Treatment of Patients with Chronic Ischemic Heart Disease (MyStromalCell Trial): A Randomized Placebo-Controlled Study
Joint Authors
Kastrup, Jens
Qayyum, Abbas Ali
Mygind, Naja Dam
Kühl, Jørgen Tobias
Jørgensen, Erik
Helqvist, Steffen
Elberg, Jens Jørgen
Kofoed, Klaus Fuglsang
Vejlstrup, Niels Groove
Fischer-Nielsen, Anne
Haack-Sørensen, Mandana
Ekblond, Annette
Mathiasen, Anders Bruun
Source
Issue
Vol. 2017, Issue 2017 (31 Dec. 2017), pp.1-12, 12 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2017-12-03
Country of Publication
Egypt
No. of Pages
12
Abstract EN
We aimed to evaluate the effect of intramyocardial injections of autologous VEGF-A165-stimulated adipose-derived stromal cells (ASCs) in patients with refractory angina.
MyStromalCell trial is a randomized double-blind placebo-controlled study including sixty patients with CCS/NYHA class II-III, left ventricular ejection fraction > 40%, and at least one significant coronary artery stenosis.
Patients were treated with ASC or placebo in a 2 : 1 ratio.
ASCs from the abdomen were culture expanded and stimulated with VEGF-A165.
At 6 months follow-up, bicycle exercise tolerance increased significantly in time duration 22 s (95%CI −164 to 208 s) (P=0.034), in watt 4 (95%CI −33 to 41, 0.048), and in METs 0.2 (95%CI −1.4 to 1.8) (P=0.048) in the ASC group while there was a nonsignificant increase in the placebo group in time duration 9 s (95%CI −203 to 221 s) (P=0.053), in watt 7 (95%CI −40 to 54) (P=0.41), and in METs 0.1 (95%CI −1.7 to 1.9) (P=0.757).
The difference between the groups was not significant (P=0.680, P=0.608, and P=0.720 for time duration, watt, and METs, resp.).
Intramyocardial delivered VEGF-A165-stimulated ASC treatment was safe but did not improve exercise capacity compared to placebo.
However, exercise capacity increased in the ASC but not in the placebo group.
This trial is registered with ClinicalTrials.gov NCT01449032.
American Psychological Association (APA)
Qayyum, Abbas Ali& Mathiasen, Anders Bruun& Mygind, Naja Dam& Kühl, Jørgen Tobias& Jørgensen, Erik& Helqvist, Steffen…[et al.]. 2017. Adipose-Derived Stromal Cells for Treatment of Patients with Chronic Ischemic Heart Disease (MyStromalCell Trial): A Randomized Placebo-Controlled Study. Stem Cells International،Vol. 2017, no. 2017, pp.1-12.
https://search.emarefa.net/detail/BIM-1201740
Modern Language Association (MLA)
Qayyum, Abbas Ali…[et al.]. Adipose-Derived Stromal Cells for Treatment of Patients with Chronic Ischemic Heart Disease (MyStromalCell Trial): A Randomized Placebo-Controlled Study. Stem Cells International No. 2017 (2017), pp.1-12.
https://search.emarefa.net/detail/BIM-1201740
American Medical Association (AMA)
Qayyum, Abbas Ali& Mathiasen, Anders Bruun& Mygind, Naja Dam& Kühl, Jørgen Tobias& Jørgensen, Erik& Helqvist, Steffen…[et al.]. Adipose-Derived Stromal Cells for Treatment of Patients with Chronic Ischemic Heart Disease (MyStromalCell Trial): A Randomized Placebo-Controlled Study. Stem Cells International. 2017. Vol. 2017, no. 2017, pp.1-12.
https://search.emarefa.net/detail/BIM-1201740
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1201740